CADTH Canadian Drug Expert Committee Final Recommendation [electronic resource] : Ixekizumab: (Taltz- Eli Lilly Canada Inc.): Indication: Moderate to Severe Plaque Psoriasis

Published:: [S.l.] : Canadian Agency for Drugs and Technologies in Health, 2016.

Finding items...

Restrictions on Access:

License restrictions may limit access.

Genre(s):

Note:

Title from content provider.

View MARC record | catkey: 26510256